Table 8. ATWB: Treatment discontinuation, corticosteroid treatment, and deaths.

Data represented as n (%); p value calculated by chi-square; *Any two or more of the above therapies (CTLA-4 inhibitors, PD-1 inhibitors, and PD-L1 inhibitors); †Any other antineoplastic treatment not belonging to the class of ICIs specifically listed.

ATWB, elevated AT levels along with elevated bilirubin; CTLA-4, cytotoxic T-lymphocyte–associated protein 4; ICI, immune checkpoint inhibitors; ICI Comb, combinations of ICIs; n, patients with IAT; PD-1, programmed cell death 1; PD-L1, programmed cell death ligand 1.

(A) Treatment class (n)	(B) Treatment discontinued (% of A)	Treatment discontinued with death < 45 days (% of B)	(C) ATWB events treated with corticosteroids (% of A)	ATWB events treated with corticosteroids with death < 45 days (% of C)
All (441)	43 (9.75)	21 (48.84)	147 (33.33)	68 (46.26)
CTLA-4 inhibitors (16)	2 (12.50)	0	3 (18.75)	1 (33.33)
PD-1 inhibitors (277)	27 (9.75)	13 (48.15)	81 (29.24)	32 (39.51)
PD-L1 inhibitors (15)	1 (6.67)	1 (100.00)	5 (33.33)	5 (100.00)
ICI Comb* (73)	5 (6.85)	2 (40.00)	34 (46.58)	16 (47.06)
ICI plus antineoplastic† (60)	8 (13.33)	5 (62.50)	24 (40.00)	14 (58.33)
p value	0.7591	0.5139	0.0317	0.0106